Trial Profile
A Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis (PrEP).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms ADAPT
- 07 Mar 2018 Results presented at the 25th Conference on Retroviruses and Opportunistic Infections
- 22 Mar 2017 Results (n=12) evaluating cases of HIV infection (seroconversion events) in the HPTN 067/ADAPT trial, published in the JAIDS
- 25 Feb 2016 Results (n=179) evaluating factors associated with PrEP coverage presented at the 23rd Conference on Retroviruses and Opportunistic Infections